Klin Farmakol Farm. 2005;19(3):175-181

Atrial fibrillation - aims of therapy

prof. MUDr. Jan Lukl CSc
I. interní klinika FN a LF UP Olomouc

Atrial fibrillation is the most common sustained tachyarrhythmia. Atrial fibrillation increases both morbidity and mortality of patients. The incidence rises not only with advancing age, but also absolutely, thus increasing the demands on both out- and in-patient care. Its complex etiology has until now rendered it impossible to respond to causative therapy. The therapeutic strategy of atrial fibrillation consists in prevention of thromboembolism, heart rate control, and rhythm control. Anticoagulation remains the most efficient prevention method of thromboembolic events. Heart rate control is usually performed by the so called AV nodal blockers or by ablative methods. To control rhythm antiarrhythmic drugs propafenone and amiodarone are most often administered. Stabilization of sinus rhythm is newly achieved by angiotensin-converting enzymes, electrical cardioversion and selective catheter ablation.

Keywords: Key words: atrial fibrillation, antiarrhythmic drugs, anticoagulation, catheter ablation, DC-cardioversion, angiotensin-converting enzyme inhibitors.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukl J. Atrial fibrillation - aims of therapy. Klin Farmakol Farm. 2005;19(3):175-181.
Download citation

References

  1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: The Framingham Study. Am Heart J 1983; 106: 389-396. Go to original source... Go to PubMed...
  2. Benjamin EJ, Levy D, Vaziri SM, D´Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844. Go to original source... Go to PubMed...
  3. Liu XK, Jahangir A, Terzic A, Gersh BJ, Hammill SC, Shen WK. Age - and sex - related atrial electrophysiologic and structural changes. American J Cardiol 2004 Aug 1; 94: 373-375. Go to original source... Go to PubMed...
  4. Friberg J, Scharling H, Gadsboll, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Amer J Cardiol 2003 Dec 15; 92: 1419-1423. Go to original source... Go to PubMed...
  5. Wolf PA, Benjamin AJ, Belanger AJ, Kannel WB, Levy D, D´Agostino RB. Secular trends in the prevalence of atrial fibrillation, the Framingham Study. Am Heart J 1996; 131: 790-795. Go to original source... Go to PubMed...
  6. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996; 156: 2537-2540.
  7. Godtfredsen J. Atrial fibrillation: course and prognosis-a follow-up study of 1212 cases. In: Kulbertus HE, Olsson Sb, Schlepper M, eds. Atrial fibrillation. Molndal: AB Hassle, 1982; 134-145.
  8. Brand FN, Abott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-3453. Go to original source... Go to PubMed...
  9. Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 1995; 76: 355-358. Go to original source... Go to PubMed...
  10. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981; 22: 143-149. Go to original source... Go to PubMed...
  11. Phillips SJ, Whisnant JP, OFallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990; 65: 344-359. Go to original source... Go to PubMed...
  12. Fetsch T, Bauer B, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394. Go to original source... Go to PubMed...
  13. Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D´Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham study. Stroke 1995; 26: 1527-1530. Go to original source... Go to PubMed...
  14. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-1457. Go to original source...
  15. European Atrial Fibrillation Trial Study Group (EAFT). Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342: 1255-1262. Go to original source...
  16. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982; 306: 1018-1022. Go to original source... Go to PubMed...
  17. Cox JL, Canavan TE, Schuessler RB, et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-426. Go to original source...
  18. Ho Sy, Sanchez-Quintana D, Cabrera JA, et al. Anatomy of the left atrium: implications for radiofrequency ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 1525-1533. Go to original source...
  19. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968. Go to original source... Go to PubMed...
  20. Ramdat Misier AR, Opthof T, van Hemel NM, et al. Increased dispersion of, ,refractoriness" in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531-1535. Go to original source... Go to PubMed...
  21. Fareh S, Villemaire C, Nattel S. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998; 98: 2202-2209. Go to original source... Go to PubMed...
  22. Attuel P, Childers R, Cauchemez B, et al. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol 1982; 2: 179-197. Go to original source... Go to PubMed...
  23. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 1996; 994: 2968-2974. Go to original source... Go to PubMed...
  24. Li D, Shingawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-2616. Go to original source... Go to PubMed...
  25. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997; 96: 3157-3163. Go to original source... Go to PubMed...
  26. Parkash R, Green MS, Kerr CR, et al. The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study. From the Canadian Registry of Atrial Fibrillation. Am Heart J 2004; 148: 649-654. Go to original source... Go to PubMed...
  27. Upshaw CB. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997; 157: 1070-1076. Go to original source...
  28. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-1314. Go to original source... Go to PubMed...
  29. Ezenkowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med 1992; 327: 1406-1412. Go to original source... Go to PubMed...
  30. SPAF Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-539. Go to original source... Go to PubMed...
  31. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Antocoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355. Go to original source... Go to PubMed...
  32. BAATAF Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-1511. Go to original source... Go to PubMed...
  33. EAFT Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-1262. Go to original source...
  34. Petersen P, Boysen G, Godfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronicm atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. Go to original source... Go to PubMed...
  35. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997; 153: 112.
  36. Benavente O, Hart R, Koudstaal P, et al. Antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke o transient ischemic attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke Module of the Cochrane Database od Systematic Reviews. Oxford: The Cochrane Collaboration; 1999. Go to original source...
  37. Morocutti C, Amabile G, Fattaposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in non-rheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28: 1015-1021. Go to original source... Go to PubMed...
  38. Olsson SB. Executive steering committee on behalf of the SPORTIF investigators. Stroke prevention with the oral direct trombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III). Lancet 2003; 362: 1691-1698. Go to original source... Go to PubMed...
  39. Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study: a randomized, controlled trial: Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Intern Med 1997; 126: 200-209. Go to original source... Go to PubMed...
  40. The Atrial Fibrillation Follow-up investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 Dec 5; 347(23): 1825-1833. Go to original source... Go to PubMed...
  41. Hagens VE, Ranchor AV, Van Sonderen EV, et al. Effect of Rate or Rhythm Control on Quality of Life in Persistent Atrial Fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43: 241-247. Go to original source... Go to PubMed...
  42. Hohnloser SH, Kuck KH. Atrial fibrillation: maintaining stability of sinus rhythm or vetricular rate control? The need for prospective data: The PIAF trial. PACE 1997; 20: 1089-1992. Go to original source... Go to PubMed...
  43. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O´Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL, AFFIRM Investigators. JACC 2004; 43: 1201-1208. Go to original source... Go to PubMed...
  44. Brignole M, Menozzi C. Control of Rapid Heart Rate in Patients with Atrial Fibrillation: Drugs or Ablation? PACE 1996r; 19: 348-356. Go to original source... Go to PubMed...
  45. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997; 29: 135-140. Go to original source... Go to PubMed...
  46. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994; 74: 884-889. Go to original source... Go to PubMed...
  47. Aronow WS, Ferlinz J. Verapamil versus placebo in atrial fibrillation and atrial flutter. Clin Invest Med 1980; 3: 35-39.
  48. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988; 9: 777-781. Go to original source... Go to PubMed...
  49. Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and flutter. Pharmacotherapy 1997; 17: 1238-1245. Go to PubMed...
  50. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent onset atrial fibrillation: results of a randomised control study. J Am Coll Cardiol 1996; 27: 1079-1082. Go to original source... Go to PubMed...
  51. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomised digoxin-controlled study. Eur Heart J 1995; 16: 521-528. Go to original source... Go to PubMed...
  52. Deedwania PC, Singh BN, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the Veterans Affairs Congestive Heart Failure Survival Trial. Circulation 1998;98: 2574-2579. Go to original source... Go to PubMed...
  53. Scheinman NM, Morady F. Nonpharmacological approaches to atrial fibrillation. Circulation 2001; 2120-2125. Go to original source... Go to PubMed...
  54. Geelen P, Brugada J, Andries E, et al. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. PACE 1997; 20: 343-348. Go to original source... Go to PubMed...
  55. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and pace trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 1998; 2: 121-135. Go to original source... Go to PubMed...
  56. Clark DM, Plumb VJ, Epstein AE, et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-1045. Go to original source... Go to PubMed...
  57. Zhuang S, Zhang Y, Mowrey KA, et al. Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation 2002; 106: 1853-1858. Go to original source... Go to PubMed...
  58. Fleck RP, Chen PS, Boyce K, et al. Radiofrequency modification of atrioventricular conduction by selective ablation of the low posterior septal right atrium in a patient with atrial fibrillation and a rapid ventricular response. PACE 1993; 16: 377-381. Go to original source... Go to PubMed...
  59. Zhang Y, Mazgalev TN. Vetricular rate control during atrial fibrillation and AV node modifications: Past, present, and future. PACE 2004; 27: 382-393. Go to original source... Go to PubMed...
  60. Ganau G, Lenzi T. Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group. J Emerg Med 1998; 16: 383-387. Go to original source... Go to PubMed...
  61. Fresco C, Proclemer A, Pavan A, Buia G, Vicentini A, Pavan D, Morgera T. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Ivestigators. Clin Cardiol 1996; 19: 409-412. Go to original source... Go to PubMed...
  62. Azpitarte J, Alvarez M, Baun O, Garcia R, Moreno E, Martin F, Tercedor L, Fernandez R. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997; 18: 1649-1654. Go to original source... Go to PubMed...
  63. Botto GL, Capucci A, Bonini W, Boriani G, Broffoni T, Barone P, Espureo M, Lombardi R, Molteni S, Ferrari G. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol 1997; 58: 55-61. Go to original source... Go to PubMed...
  64. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. The American Journal of Cardiology 1997; 79: 418-423. Go to original source... Go to PubMed...
  65. Boriani G, Biffi M, Capucci A, Botto G, Broffoni T, Ongari M, Trisolino G, Rubino I, Sanguinetti M, Branzi A, Magnani B. Conversion of recent-onset atrial fibrillation to sinus rhythm: Effects of different drug protocols. PACE 1998; 21: 2470-2474. Go to original source... Go to PubMed...
  66. Lukl J, Řezáčová M, Černošek B, Heinc P. Užití Amiodaronu v léčbě míhání síní odolného proti digoxinu. I. Schopnost amiodaronu převést míhání síní na sinusový rytmus a jeho krátkodobé udržení. Vnitřní lékařství 1985; 31: 177-181. Go to PubMed...
  67. Kochiadakis GE, Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of Amiodarone for the Termination of Persistent Atrial Fibrillation. Am J Cardiol 1999; 831): 58-61. Go to original source... Go to PubMed...
  68. Roy D, Talajic M, Dorian P, Connoly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. New Engl J Med 2000; 342: 913-920. Go to original source... Go to PubMed...
  69. Lukl J, Řezáčová M, Černošek B, Heinc P. Užití amiodaronu v léčbě míhání síní odolného proti digoxinu. II. Schopnost amiodaronu dlouhodobě udržet sinusový rytmus. Vnitřní lékařství 1986; 32: 84-87. Go to PubMed...
  70. Campbell RF. ACE inhibitors and arrhythmias. Heart 1996; 76: 79-82. Go to original source... Go to PubMed...
  71. Fletcher RD, Cintron RB, Johnson J, Orndorff J, Carson V. Enalapril decreases the presence of ventricular tachycardia in patients with chronic congestive heart failure. Circulation 1993; 87 (supple VI): 49VI-55VI.
  72. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380. Go to original source... Go to PubMed...
  73. Madrid AH, Bueno MG, Rebollo JMG, Marín I, Pe G, Cano JM, Cabeza P, Moro C. Use of Irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002; 106: 331. Go to original source... Go to PubMed...
  74. Ueng KCH, Tsai TP, Yu WCH, Tsai CHF, Lin MCH, Chan KCH, Chen CHY, Wu DJ, Lin CHS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur Heart J 2003; 24: 2090-2098. Go to original source... Go to PubMed...
  75. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-46. Go to original source... Go to PubMed...
  76. Carboni A, Finardi A, Rolli A, et al. Safety and efficacy of transthoracic electrical cardioversion with biphasic shock in persistent atrial fibrillation (abstr). Europace 2001; 2: A16. Go to original source...
  77. Boriani G, Bifi M, Camanini C, et al. Transvenous low energy internal cardioversion for atrial fibrillation: a review of clinical application and future developments. PACE 2001; 24: 99-107. Go to original source... Go to PubMed...
  78. Daoud EG, Timmermans C, Fellows C, et al. Intial clinical experience with ambulatory use of an implantable atrial defibrillator for conversion of atrial fibrillation. Circulation 2000; 102: 1407-1413. Go to original source... Go to PubMed...
  79. Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991; 101: 584-592. Go to original source...
  80. Arcidi JM, Millar RC. Evolution of the maze III procedure: are modifications necessary? Thorac Cardiovasc Surg 1999; 47: 362-364. Go to original source... Go to PubMed...
  81. Haissaguerre M, Gencel L, Fischer B, et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5: 1045-1052. Go to original source... Go to PubMed...
  82. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666. Go to original source... Go to PubMed...
  83. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102: 2463-2465. Go to original source... Go to PubMed...
  84. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000; 102: 2619-2628. Go to original source... Go to PubMed...
  85. Marrouche NF, Martin DO, Wazni O, et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation 2003; 107: 2710-2716. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.